What Loss of Chance Means in a Cancer Claim

Loss of chance is a way of measuring harm. In a cancer case it describes the survival prospect, treatment option or treatment decision that a patient lost because a diagnosis was missed or delayed. The claim isn't for the cancer itself. It's for the better position the patient would probably have been in if the negligence hadn't happened.

This page deals only with loss of chance in cancer misdiagnosis and delayed diagnosis claims. For the doctrine as it applies across all injury types, see our guide to the general loss of chance doctrine. Here the focus is narrower and more practical: how the lost chance is proved, valued and presented when the illness is cancer.

The idea matters most in cancer because cancer outcomes are tied so closely to stage at diagnosis. A delay can move a tumour from an early, treatable stage to an advanced one. The HSE National Cancer Control Programme publishes GP referral guidelines for suspected cancer (NCCP, accessed June 2026) precisely so that warning signs trigger timely investigation.^[11] That shift in stage is where the lost chance lives, and it is why oncology evidence sits at the centre of every claim of this kind.

Why a Survival Chance Below 50% Does Not End Your Claim

Many people assume that a poor prognosis means there's no case. If the chance of survival was always less than half, the reasoning goes, then nothing was really lost. In Ireland that assumption is wrong, and it's the single most common reason patients don't seek advice.

Irish law treats the lost chance as a harm in its own right. The Supreme Court in Philp v Ryan compensated a patient for the opportunity he lost to consider and receive timely treatment. The medical evidence could not prove that earlier diagnosis would have extended his life on the balance of probabilities, yet the lost opportunity was still compensable.^[2]

This is where Irish law parts company with England. In Gregg v Scott, a delay reduced a patient's survival chance from 42% to 25%. The House of Lords refused recovery because the chance had been below 50% even with prompt care.^[4] Irish courts have not followed that restrictive route. The contrast is set out below.

Gregg v Scott is English authority. It is included here only to show how the Irish position differs and does not state the law in Ireland.

Philp v Ryan and the Irish Position

Philp v Ryan is the Supreme Court decision that anchors loss of chance in Irish cancer claims. The plaintiff was referred with abdominal symptoms, and a consultant treated him for prostatitis while missing prostate cancer. The correct diagnosis came about eight months later, by which point the disease had advanced.^[2]

The medical evidence could not establish that the eight-month delay had definitely shortened his life. Under a strict reading of causation that would have ended the claim. The Supreme Court took a different view. It held that the patient had been wrongfully deprived of the opportunity to consider his treatment options at the proper time. That deprivation, and the distress that came from it, was compensable.^[2]

The award and why aggravated damages were added

The High Court awarded €45,000. The Supreme Court increased the total to €100,000.^[5] A substantial part of the increase reflected aggravated damages, because it emerged that the defendant had altered a clinical note after proceedings began and had not disclosed the change.^[6] Aggravated damages are rare in negligence. They are not compensation for the clinical error itself, but for oppressive or deceitful conduct, and the falsification of records met that threshold.

Loss of Chance and Strict Causation: The Dual-Track Approach

In practice a cancer-delay claim is often run on two tracks at once, because Irish law holds a tension that experienced practitioners have to manage. Philp v Ryan recognised the lost chance. The following year, the Supreme Court in Quinn v Mid-Western Health Board reaffirmed the strict "but for" test and dismissed a claim where causation for the physical injury could not be proved.^[7] The Quinn judgment did not refer to Philp, which left the exact boundaries of the doctrine open.

In practice the two cases answer different questions. Quinn governs whether the negligence caused the physical injury. Philp governs whether the patient lost a real opportunity worth compensating. Because of that distinction, a claim is often pleaded on two tracks at the same time. Our guide to how causation is proven explains the underlying tests in full.

Pleading both protects the claimant. If the strict causation argument falls short under cross-examination, the loss-of-chance argument can still succeed on its own footing. It helps to be clear about the order. Orthodox causation on the balance of probabilities is the primary route, and loss of chance is the alternative the court reaches for when that primary route cannot be proved. It is a fallback, not a shortcut around proving harm.

How the Irish Position Has Developed

Loss of chance in Ireland is best understood as a line of Supreme Court and Court of Appeal decisions rather than a single rule. The leading cancer authority, Philp v Ryan, opened the door, later decisions tested its edges, and the most recent case sets the evidential bar. The cluster's best-known cancer case, Morrissey v HSE, sits within this line. It reaffirmed the Dunne standard of care and confirmed the HSE's non-delegable duty to patients in the CervicalCheck programme.^[12]

The practical reading is that Ireland remains more open than England on a sub-50% chance, while still demanding rigorous proof that a chance existed at all. The Philp and Quinn tension has not been formally reconciled by a later Supreme Court ruling, so both still matter.

Does loss of chance apply to every cancer delay?

No. Many claims succeed on ordinary causation, where the evidence proves the delay changed the outcome on the balance of probabilities. Loss of chance is the route the court turns to when that cannot be proved but a real opportunity was still lost. It widens access to compensation, yet it does not remove the need to prove a genuine chance existed.

How the Lost Chance Is Valued

There's no fixed tariff for a lost chance, and no percentage formula that converts a survival figure into an award. Clinical negligence general damages are assessed case by case rather than through the standard Personal Injuries Guidelines tariff used for routine injuries, and any figure depends entirely on the evidence. What a court is valuing usually falls into a small number of recognised heads.

• Lost years or reduced life expectancy, where the delay shortened the time the patient can expect.
• Harsher treatment, such as the move from limited surgery to a radical procedure, full chemotherapy or extended radiotherapy.
• Lost quality of life, including lasting effects of the more aggressive treatment that became necessary.
• The lost opportunity and choice to make informed decisions at the right time, with the distress that the loss causes.

The stage-shift gap

The clearest way to see the harm is the stage-shift gap. This is the difference between the outcome the patient should have had with a timely diagnosis and the outcome they actually face. Independent oncologists map it using the contemporaneous records, tumour grading, lymph node status and recognised prognostic tools.

Irish data shows why stage matters so much. The National Cancer Registry reports that some cancers caught early, such as melanoma, uterine and prostate cancer, can reach five-year net survival of up to 100%, while late presentation at stage four remains common for head and neck, pancreatic and lung cancers, with much poorer outcomes.^[13] A delay that pushes a cancer down that curve is the measurable harm a loss-of-chance claim addresses.

Take breast cancer as an illustration. A delay that allows disease to move from an early stage to an advanced one can change both the prognosis and the treatment pathway. The shift can run from limited surgery toward radical surgery, full node clearance and systemic chemotherapy. The same logic runs across our wider guidance, including oesophageal and stomach cancer and the faster-moving cancers in the cancer misdiagnosis section.

Where the delay caused a clear, provable reduction in life expectancy, the claim shifts toward reduced life expectancy and stage-shift damages. Loss of chance does the work where that reduction cannot be proved on the balance of probabilities but a real opportunity was still lost. Both sit alongside general and special damages, which cover pain and suffering and the financial losses that follow. Our guide to medical negligence compensation explains how those amounts are approached in Ireland.

A worked illustration

The following scenario is anonymised and illustrative. It carries no figure and is not a prediction of any outcome. Imagine a patient whose persistent symptoms are attributed to a benign cause for nine months before cancer is diagnosed. Two questions then drive the claim.

First, the strict causation question. Would timely diagnosis probably have changed the physical outcome, on the balance of probabilities? If the oncology evidence shows the cancer was already advanced and incurable nine months earlier, this track may fail. Second, the loss-of-chance question. Even if the physical outcome cannot be proved to have changed, was the patient deprived of a real and substantial chance, such as earlier, less invasive treatment or an informed choice about care? If so, the lost opportunity may still be compensable on the Philp footing. The value attaches to what was lost, assessed on the evidence, not to a fixed percentage of the cancer outcome.

Where Loss-of-Chance Claims Still Fail

Loss of chance isn't automatic, and honesty about its limits matters. The doctrine is a route to compensation once a real lost chance is shown. It doesn't remove the need to prove that a chance existed at the time of the alleged negligence.

The clearest recent warning is Crumlish v HSE. The Court of Appeal dismissed a delayed breast cancer claim in 2024 at what it called the first causation hurdle.^[3] The plaintiff alleged a five-month delay between an initial clinic visit and diagnosis. Her case relied on a tumour doubling-time estimate from an academic paper, used to argue the cancer must have been detectable earlier.^[8]

The court rejected that reasoning. It accepted expert evidence that tumour growth is not an exact science and that a generalised doubling-time figure cannot reliably track a cancer backward in isolation.^[9] On the evidence, the cancer was likely undetectable at the first visit, so there was no chance to lose. The decision shows that genuine cancer and a genuine delay aren't enough on their own. There must be credible evidence that a real and substantial chance existed when the negligence is said to have occurred. The detailed mechanics of these causation arguments are set out in our guide to how causation is proven in a cancer claim.

Time Limits and How These Claims Are Built

How do you prove a loss of chance?

You prove it with independent oncology evidence and a precise treatment timeline. The expert addresses the stage of the cancer at the time of the negligence, whether earlier detection was realistic, and what difference timely treatment would probably have made. That evidence is what turns a suspected delay into a provable lost chance.

Most adult medical negligence claims in Ireland must begin within two years less one day. The clock usually runs from the date of knowledge rather than the date of the negligence. That means the date you first knew, or ought reasonably to have known, that you had a significant injury connected to negligent care. Cancer cases often turn on that distinction, and the detail is covered in our guide to the date of knowledge.

Building one of these claims is evidence-intensive. The strength of the case depends heavily on early, independent oncology evidence and on a careful timeline of every consultation, test and result. In our experience, the cases that hold up are the ones where expert input on detectability and stage is obtained early, before positions harden. Clinical negligence actions in the High Court are now managed under dedicated procedures introduced in April 2025. These expect expert reports to be well advanced before a trial date is sought, so getting expert input early is more important than ever.^[10]

Where a delay has tragically proved fatal, a separate claim can be brought by dependants under the Civil Liability Act 1961. We explain that route in our guidance on cancer claims after a death.

References

1. Philp v Ryan & Anor [2004] IESC 105, Supreme Court of Ireland, recognising loss of chance below a 50% probability. See case summary.^↩
2. Philp v Ryan & Anor [2004] IESC 105, [2004] 4 IR 241 (Fennelly J), Supreme Court of Ireland, judgment of 16 December 2004. Primary judgment via BAILII (accessed June 2026) and vLex Ireland (accessed June 2026).^↩
3. Crumlish v Health Service Executive [2024] IECA 244 (Noonan J, with Power and Binchy JJ), Court of Appeal, judgment of 15 October 2024, dismissing the appeal because the cancer was not shown to be detectable at the earlier visit. Primary judgment via BAILII (accessed June 2026). Reported via Irish Legal News (accessed June 2026).^↩
4. Gregg v Scott [2005] UKHL 2, House of Lords (England and Wales), refusing recovery where survival chance was below 50%. Included for contrast only and not Irish law.^↩
5. Philp v Ryan & Anor [2004] IESC 105, award increased from €45,000 to €100,000 by the Supreme Court.^↩
6. Aggravated damages in Philp v Ryan for the altered clinical note. See the Law Society and Judicial commentary on aggravated damages in Irish law via our aggravated damages guide.^↩
7. Quinn (a minor) v Mid-Western Health Board [2005] IESC 19, [2005] 4 IR 1 (Kearns J), Supreme Court of Ireland, judgment of 8 April 2005, reaffirming the strict "but for" causation test. Judgment via BAILII (accessed June 2026).^↩
8. Crumlish v HSE: reliance on a tumour doubling-time estimate from an academic paper. Reported via The Irish Times.^↩
9. Crumlish v HSE: Court of Appeal acceptance that tumour growth is not an exact science. Commentary via Mason Hayes Curran.^↩
10. High Court Practice Directions HC131 and HC132, in force 28 April 2025, on clinical negligence trial readiness and the Clinical Negligence List. Courts Service of Ireland. See our guide to notice of trial and case management.^↩
11. HSE National Cancer Control Programme, GP Referral Guidelines for suspected cancer. HSE.ie (accessed June 2026).^↩
12. Morrissey & anor v Health Service Executive & ors [2020] IESC 6, Supreme Court of Ireland, judgment of 19 March 2020, reaffirming the Dunne standard and the HSE's non-delegable duty in cervical screening. Judgment via BAILII (accessed June 2026). See our case summary.^↩
13. National Cancer Registry Ireland, Cancer in Ireland 1994 to 2021: Annual Statistical Report, on the impact of stage at diagnosis on outcomes. NCRI.ie (accessed June 2026).^↩